Search Results for "Fingolimod Hplc Method"

01:14 EDT 27th March 2015 | BioPortfolio

Matching Channels

DNA-FISH Probes

Fluorescent in situ hybridization (FISH) is a sensitive and accurate technique that allows the detection of chromosome aberrations. In this method, a single-stranded fluorescent-labeled nucleic acid...

Spirometry Test

The gold standard in lung testing In the same way that blood pressure measurements provide a simple yet effective screening method for cardiovascular disease, spirometry tests can help to unmask t...

Herpes simplex virus HSV 1 HSV 2 HHV 1 HHV 2

Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also known as Human herpes virus 1 and 2 (HHV-1 and -2), are two members of the herpes virus family that infect humans. HSV-1 and HSV-2 cause the vira...

Testicular Cancer

Testicular cancer represents only 1 per cent of all cancers in men, but it is the single biggest cause of cancer-related deaths in men aged 15-35 years in the UK. The causes of testicular cancer and...

Breast Implants - Augmentation

Breast implants are medical devices that are used to augment breast size or to reconstruct the breast following mastectomy or to correct a congenital abnormality. Breast implants consist of a silico...

Matching News

Advanced Selectivity Phases for Powerful UHPLC and HPLC Method Development

Advanced Chromatography Technologies’ range of Advanced Selectivity phases offers chromatographers an extremely powerful tool for UHPLC and HPLC method development. These phases incorporate the ...

Fingolimod Trial in Progressive MS Misses Endpoint

Novartis reports that topline results of the INFORMS trial show no benefit over placebo on disability measures for oral fingolimod treatment. Medscape Medical News

PML in MS Patients Making Natalizumab-to-Fingolimod Switch

A new report describes several cases of PML seen in patients with MS receiving fingolimod, all but 1 of which were treated previously with natalizumab. Authors say this patient had neuromyelitis optic...

HPLC Column Addresses Difficult-to-Resolve Compounds

Phenomenex introduces the Kinetex C8 5-micron core-shell HPLC column. The used C8 phase delivers retention for the analysis of hydrophobic and “sticky” compounds. In combination with Kinetex Core-...

Analytical Method Comparability in Registration and Post-Approval Stages: A Risk-Based Approach

A risk-based approach is recommended for analytical method comparability for HPLC assay and impurities methods.

Novartis provides update on fingolimod Phase III trial in primary progressive MS

Novartis announced that the Phase III INFORMS study in primary progressive multiple sclerosis (PPMS) did not show a significant difference between fingolimod and placebo on a combination of disability...

Routine Generation of Powder Samples from HPLC Fractions

Genevac reports that its HT Series II Evaporator using the Fast Lyophilisation, or LyoSpeed process is enabling a growing number of pharmaceutical labs to routinely dry HPLC fraction samples to a powd...

Novartis: Phase III-Studie mit Gilenya (Fingolimod) erreicht Ziele nicht

Basel (awp) - Novartis vermeldet einen Misserfolg mit dem Produkt Gilenya (Fingolimod). Eine Phase-III-Studie zu einer bestimmten Form von Multipler Sklerose (MS) habe den primären Endpunkt nicht e.....

Matching PubMed Articles

Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia.

To assess whether pretreatment-lymphocyte counts, treatment before fingolimod, age, sex, or body mass index (BMI) affects the risk of fingolimod-induced lymphopenia in patients with relapsing-remittin...

Second-Line Therapy with Fingolimod for Relapsing-Remitting Multiple Sclerosis in Clinical Practice: The Effect of Previous Exposure to Natalizumab.

Background: To evaluate efficacy and safety of fingolimod for relapsing-remitting multiple sclerosis, particularly in patients previously exposed to natalizumab. Method: Prospective observational sing...

Fingolimod Prevents Blood-Brain Barrier Disruption Induced by the Sera from Patients with Multiple Sclerosis.

Effect of fingolimod in multiple sclerosis (MS) is thought to involve the prevention of lymphocyte egress from lymphoid tissues, thereby reducing autoaggressive lymphocyte infiltration into the centra...

Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease.

Fingolimod is the first oral immunomodulatory therapy approved for highly active relapsing remitting multiple sclerosis. Based on the distribution pattern of fingolimod interacting sphingosine-1-phosp...

Experience with Fingolimod in Clinical Practice.

Aim: To report experience with fingolimod in clinical practice. Design/Methods: Patients in an academic medical center who were prescribed fingolimod from October 2010 to August 2011 were identified t...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement